ViroVet is a pioneering company developing innovative technologies to combat viral diseases in livestock. They focus on antiviral drugs for complex respiratory illnesses and novel vaccines to protect pigs against viral infections. With the livestock industry representing over €100 billion globally, viral diseases cause billions in annual losses and threaten the world’s supply of animal protein.

ViroVet’s mission is to provide effective solutions, used alone or alongside vaccines and biosecurity measures, that equip breeders, governments, and international organizations with the tools to fight both endemic and epizootic diseases.

As the global population grows, the demand for protein-rich diets increases, while factors such as livestock density, global trade, and climate change amplify the risk of viral disease spread. ViroVet has engaged key opinion leaders in livestock medicine, validating the strong market potential for its antiviral drugs and vaccines. These experts recognize ViroVet’s potential to reduce antibiotic use and transform livestock health worldwide.